Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...

By Deena Beasley (Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing ...

The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.

Shares of Sarepta Therapeutics Inc. have lost more than 26% this week, heading for their worst such performance in over a ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by analysts at HC Wainwright in ...

In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...

Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Sarepta Therapeutics's revenues have an average growth rate of 29.5% with operating expenses growing at 14.4%. The company's ...

The firm's stock price dropped 27 percent on Tuesday following the news that the young man died from acute liver failure after getting Elevidys.

Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that ...